High dose D-serine in the treatment of schizophrenia
Introduction
Phencyclidine (PCP) and related compounds induce a psychotic state that closely resembles schizophrenia by blocking N-methyl-d-aspartate (NMDA)-type glutamate receptors (Javitt and Zukin, 1991). Agonists of the NMDA positive allosteric modulatory site, such as glycine and D-serine, reverse behavioral effects of PCP preclinically, suggesting potential therapeutic utility. Disturbances in D-serine metabolism are also reported (Kantrowitz and Javitt, 2009). To date, several studies of D-serine in schizophrenia have been conducted using a dose of ∼ 30 mg/kg with positive results across studies (Javitt, 2008). Nevertheless, ideal doses of D-serine in clinical studies remains to be determined. In this study, we evaluated clinical effects of D-serine at doses > 30 mg/kg/d with emphasis on both safety and efficacy.
Section snippets
Inclusion criteria
1) Aged 18-60; 2) SCID diagnosis of schizophrenia/schizoaffective disorder (First, et al., 1997); 3) Positive and Negative Symptom Scale (PANSS) (Kay, et al., 1987) negative symptom score > 20 and total score between 60-110; 4) Stable Clinical Global Impression Scale (CGI) (Guy, 1976) for two consecutive weeks; 5) Simpson Angus Scale (SAS) (Simpson and Angus, 1970) score ≤ 12; 6) Calgary Depression Inventory for Schizophrenia (CDDS) (Addington, et al., 1994) score ≤ 10 and suicide less than
PANSS
Across doses, significant, moderate effect-size improvements were observed on PANSS total and subscales (Fig. 1 a-d and Supplement 1). Significant improvement was seen on the total PANSS within all three phases (p < 0.05), and across all three subscales for the 120 mg/kg dose.
MATRICS
Baseline scores were ∼ 2 sd below normative levels on the MATRICS, suggesting clinically significant baseline cognitive deficits (Fig. 2). There were no significant differences in baseline mean composite (F2,44= 1.5;p = 0.23) or
Discussion
Similar to prior studies (Javitt, 2008), significant improvement was observed on PANSS positive, negative and total scores. Significant baseline correlations were observed between reduced D-serine levels and negative symptoms and between peak D-serine on day 1 and subsequent improvement in negative symptoms, consistent with prior clinical findings (Neeman et al., 2005, Sumiyoshi et al., 2004). As plasma D-serine levels were unknown at the time when ratings were performed, these are unlikely to
Role of funding source
This project was funded by NIH grant (U01 MH074356). Preclinical/clinical toxicology in support of the project was provided by 5R44AT000810 and a grant from the Stanley Foundation. The NIH and Stanley Foundation had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the paper for publication.
Contributors
Dr. Javitt, Woods, Malhotra, Cornblatt and D'Souza designed the study. Dr. Kantrowitz, Woods and Javitt performed the statistical analysis. Ms. Balla and Dr. Suckow performed the plasma D-serine analysis. Ms. Silipo and Dr. Saska coordinated patient recruitment. Dr. Kantrowitz wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.
Conflict of Interest
Daniel Javitt holds intellectual property rights for use of glycine, D-serine, and glycine transport inhibitors in the treatment of schizophrenia; he is a major shareholder in Glytech and Amino Acid Solutions; he has received consulting payments from Glytech. Scott Woods has received a use patent for a different indication; royalties devolve to Yale University to further his research and not to him personally. All of the other authors have no potential conflicts of interest relevant to this
Acknowledgments
Funded by NIH grant (U01 MH074356) to DCJ.
References (19)
- et al.
Specificity of the Calgary Depression Scale for Schizophrenics
Schizophr. Res.
(1994) - et al.
Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N-tert.-butyloxycarbonyl-L-cysteine and o-phthaldialdehyde
J Chromatogr Biomed Appl
(1992) - et al.
Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis
Schizophr. Res.
(2004) Glycine transport inhibitors and the treatment of schizophrenia
Biol. Psychiatry
(2008)- et al.
Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia
Brain Res.
(2004) Negative symptoms in schizophrenia
Arch. Gen. Psychiatry
(1982)A rating scale for drug-induced akathisia
Br. J. Psychiatry
(1989)Statistical Power Analysis for the Behavioral Sciences
(1988)- et al.
Tardive dyskinesia and new antipsychotics
Curr. Opin. Psychiatry
(2008)
Cited by (206)
d-Amino acids in biological systems
2023, ChiralityDose Finding for D-Serine Enhancement of Plasticity in Schizophrenia
2023, Biological PsychiatryDistinctive effects of NMDA receptor modulators on cerebral microcirculation in a schizophrenia mouse model
2023, Biochemical and Biophysical Research CommunicationsD-amino Acids Ameliorate Experimental Colitis and Cholangitis by Inhibiting Growth of Proteobacteria: Potential Therapeutic Role in Inflammatory Bowel Disease
2023, Cellular and Molecular Gastroenterology and HepatologyA narrative review of treatment interventions to improve cognitive performance in schizophrenia, with an emphasis on at-risk and early course stages
2022, Psychiatry ResearchCitation Excerpt :Numerous clinical trials have been performed utilizing NMDA receptor agonists (glycine and D‑serine), the NMDA receptor partial agonist, d-cycloserine (Coyle and Tsai, 2004), and GlyT1 inhibitors (e.g., sarcosine and bitopertin) (Chang et al., 2020; Umbricht et al., 2014a). Initial studies showed improvement in cognitive function with NMDA receptor enhancers as an adjunct treatment to conventional antipsychotic drugs (Goff et al., 1999; Heresco-Levy et al., 1996, 1998; Kantrowitz et al., 2010; Tsai et al., 1998). Furthermore, a recent phase 2 trial found that 12 weeks of treatment with a GlyT1 inhibitor, BI 425,809, improved cognition in 509 patients with SCZ (Fleischhacker et al., 2021).